Pharmafile Logo
Pharmafocus logo
Advanced Search

Neurology

Showing 15 posts of 114 posts found.

HonorHealth Research Institute announces first patient dosed with new stroke treatment

February 2, 2026
Research and Development HonorHealth Research Institute, Neurology, ischemic stroke

HonorHealth Research Institute, a research institution collaborating with a wide range of experts to produce new treatments and devices, has …

News

Five Facts about spinal muscular atrophy

January 28, 2026
Medical Communications Five Facts, Neurology, early diagnosis, five types, gene therapy, muscle weakness, spinal muscular atrophy

1 Spinal muscular atrophy (SMA) is a genetic disease involving the loss of motor neurons in the spinal cord.1 Its …

Feature

Spike in searches relating to spinal muscular atrophy following Jesy Nelson disclosure

January 19, 2026
Medical Education Neurology, spinal muscular atrophy

New research from the Centre for Surgery has shown a significant rise in Google searches relating to spinal muscular atrophy …

News

Biogen’s high-dose Spinraza regimen receives European Commission approval for spinal muscular atrophy

January 19, 2026
Research and Development Biogen, Neurology, Spinraza, spinal muscular atrophy

Biogen’s Spinraza (nusinersen) has received approval from the European Commission (EC) as a new high-dose regimen for the treatment of …

News

Teva’s Ajovy significantly reduces migraine in children and adolescents

January 12, 2026
Research and Development Neurology, Teva, ajovy, migraine

Teva’s Ajovy (fremanezumab) has demonstrated significant reduction in monthly migraine and headache days in children and adolescents with episodic migraine …

News

EpilepsyGTx raises $33m for focal refractory epilepsy gene therapy

December 10, 2025
Research and Development EpilepsyGTx, Neurology, epilepsy

EpilepsyGTx, a biotechnology company researching and developing gene therapies for the treatment of refractory epilepsy, has announced $33m raised in …

News

UCB presents positive results for fenfluramine in CDKL5 deficiency disorder

December 8, 2025
Research and Development Neurology, UCB, epilepsy

UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can significantly reduce the frequency of …

News

Teva announces positive results from trial of AJOVY for migraine

December 5, 2025
Research and Development Neurology, Teva, migraine

Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its treatment for chronic (CM) and …

News

Rare and severe epilepsies – current treatments and advance therapeutics

August 29, 2025
Medical Communications, Research and Development Neurology, UCB, epilepsy, epilepsy treatment, rare epilepsies

The current forms of immunotherapy, how T cell therapy works and what the future holds

Feature
epilepsy-623346_960_720

Epilepsy Research Institute opens 2025-26 grant round with new awards

August 21, 2025
Medical Communications, Research and Development Neurology, epilepsy, funding programme, medical research

The Epilepsy Research Institute has opened its 2025-26 Grant Round, offering a wide range of funding opportunities designed to support …

News

Five Facts about epilepsy

August 21, 2025
Medical Communications Five Facts, Neurology, epilepsy, neurological condition, seizures

1 Epilepsy occurs when the normal electrical activity in the brain changes. For many, the cause is unclear, but genes …

Feature
brain_anatomy_medical_head_skull_digital_3_d_x_ray_xray_psychedelic_3720x2631

FDA decision on Neurizon’s ALS therapy delayed until October

August 18, 2025
Medical Communications Coya Therapeutics, Neurizon, Neurology, US Food and Drug Administration, amyotrophic lateral sclerosis

Neurizon Therapeutics has announced that the US Food and Drug Administration (FDA) will delay its decision on the company’s Clinical …

News
Patients image

PhotoPharmics expands Parkinson’s Trial into further US states

August 14, 2025
Research and Development Neurology, PhotoPharmics, clinical trial, neurodegenerative disorders

US-based PhotoPharmics, has expanded enrollment in its Light for PD clinical trial beyond its original 300 participants, opening new sites …

News

PLL Therapeutics to present ALS research strategy at Bioshares Biotech Summit

August 7, 2025
Medical Communications, Research and Development Bioshares Biotech Summit, Neurology, PLL Therapeutics, amyotrophic lateral sclerosis, neurodegenerative diseases

French biotech, PLL Therapeutics, will present its approach to early detection and treatment of Amyotrophic Lateral Sclerosis (ALS) at the …

News
sanofi

Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline

August 6, 2025
Mergers and Acquisitions Alzheimer's disease, Corporate, Neurology, Sanofi, Vigil Neuroscience, neurodegenerative diseases

Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology company specialising in neurodegenerative diseases. …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026